By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
ScienceabodeScienceabode
  • Home
  • News & Perspective
    News & PerspectiveShow More
    Microorganism that causes rare but severe eye infections detected in NSW coastal areas
    By Admin
    Scientists identify common cause of gastro in young children and adults over 50 years old
    By admin
    AI reveals hidden traits about our planet’s flora to help save species
    By admin
    Eye drops slow nearsightedness progression in kids, study finds
    By admin
    Using AI to create better, more potent medicines
    By admin
  • Latest News
    Latest NewsShow More
    Researchers develop new robot medics for places doctors are unable to be
    By Admin
    Even thinking about marriage gets young people to straighten up
    By admin
    Study: People tend to locate the self in the brain or the heart – and it affects their judgments and decisions
    By admin
    UCLA patient is first to receive successful heart transplant after using experimental 50cc Total Artificial Heart
    By admin
    Via Dying Cells, UVA Finds Potential Way to Control Cholesterol Levels
    By admin
  • Health
    Health
    The World Health Organization defines health as “a state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity.”…
    Show More
    Top News
    World’s largest study of brain volume reveals genetic links to ADHD, Parkinson’s Disease 
    October 26, 2024
    Chemicals produced by fires show potential to raise cancer risk
    November 11, 2024
    Rising rates of head and neck cancers in England
    October 26, 2024
    Latest News
    Game-Changer in Emergency Medicine: New AI Test Flags Sepsis Hours Before Symptoms Worsen
    June 4, 2025
    Perfumes and lotions disrupt how body protects itself from indoor air pollutants
    June 3, 2025
    Medical Milestone: Surgeons Perform First-Ever Human Bladder Transplant
    May 20, 2025
    A Downside of Taurine: It Drives Leukemia Growth
    May 19, 2025
  • Environment
    EnvironmentShow More
    Perfumes and lotions disrupt how body protects itself from indoor air pollutants
    By Admin
    Arsenic exposure linked to faster onset of diabetes in south Texas population 
    By Admin
    Antarctica vulnerable to invasive species hitching rides on plastic and organic debris
    By Admin
    New substrate material for flexible electronics could help combat e-waste
    By Admin
    Bacteria ‘nanowires’ could help scientists develop green electronics
    By Admin
  • Infomation
    • Pricavy Policy
    • Terms of Service
  • Jobs
  • Application Submission
Notification Show More
Aa
ScienceabodeScienceabode
Aa
  • Home
  • Health
  • Anatomy
  • Jobs Portal
  • Application Submission
  • Categories
    • Health
    • Anatomy
    • Food & Diet
    • Beauty Lab
    • News & Perspective
    • Environment
  • More Foxiz
    • Blog Index
    • Sitemap
Follow US
Scienceabode > Blog > Health > QIMR Berghofer research leads to new treatment for potentially deadly Graft-versus-Host Disease
Health

QIMR Berghofer research leads to new treatment for potentially deadly Graft-versus-Host Disease

Admin
Last updated: 2024/11/24 at 6:45 PM
By Admin
Share
4 Min Read
SHARE

A discovery by QIMR Berghofer researchers has led to the development and approval of a new treatment for chronic Graft-versus-Host Disease (GVHD),
the major cause of serious complications and death in blood cancer patients who receive vital stem cell transplants.

The United States Federal Drug Administration (FDA) has fast-tracked approval of a drug based on QIMR Berghofer researcher Dr Kelli MacDonald’s findings, a decade after her breakthrough discovery of an antibody that could prevent chronic GVHD.

Chronic GVHD occurs when transplanted cells attack the recipient’s organs and tissues and cause scarring which leads to debilitating and often long-lasting health problems, particularly in the skin and lungs.

Rigorous clinical trials have shown the FDA-approved treatment known as Axatilamab, successfully suppresses harmful immune cells, preventing the development of chronic GVHD. These results have been published in the prestigious New England Journal of Medicine.

- Advertisement -
MedBanner_Skyscraper_160x600_03/2018

The drug is expected to meet the urgent needs of a large proportion of patients with chronic GVHD who fail to respond to initial steroid based therapy.

“This is an important and exciting development for people with GVHD and has been over a decade in the making from our initial research,” Dr MacDonald said.

“Until recently, there has been no satisfactory treatment for people affected by this debilitating condition which causes inflammation and fibrosis in tissues throughout the body. However, this new treatment has significantly reduced symptoms in up to 75 per cent of patients.

“I’m incredibly proud that a world-first pre-clinical discovery made right here in Brisbane is having such a tangible impact on the lives of patients across the world.”

The work began in 2014, when Dr MacDonald’s lab at QIMR Berghofer identified both the cellular process causing chronic GVHD, and the antibody that could block this process and prevent the disease’s development.

Healthcare providers will soon be able to access full prescribing information on the FDA’s website as the drug becomes available in the USA. It is not yet known when the treatment will become available in Australia.

Bone marrow or stem cell transplants are critical, life-saving treatments for blood cancer patients, but helping those who suffer the complication of chronic GVHD has been a major unmet need.

“This approval is a big step forward for people dealing with the challenges of chronic GVHD and offers a new option for those who have struggled to find effective treatment,” Dr MacDonald said.

“It really is a dream to see your research progress from the laboratory to improve the outcome of patients. The ability of our research to lead to new drug approval really emphasises the importance and quality of the expertise in transplant immunology, developed over two decades at QIMR Berghofer. It also highlights the persistence and timeframes needed to understand and address clinical problems in the lab.”

Dr MacDonald’s research was funded by grants from the Rio Tinto Ride to Conquer Cancer, the National Health and Medical Research Council (NHMRC) and Cancer Council Queensland.

Source: QIMR Berghofer.

Published on November 24, 2024

TAGGED: fibrosis, GVHD, inflammation
Admin November 24, 2024 November 24, 2024
Share This Article
Facebook Twitter Copy Link Print

Fast Four Quiz: Precision Medicine in Cancer

How much do you know about precision medicine in cancer? Test your knowledge with this quick quiz.
Get Started
Even in Winter, Life Persists in Arctic Seas

(USCGC Healy breaking through the Bering Sea waves. Credit: Chantelle Rose/NSF)   Despite…

A Biodiversity Discovery That Was Waiting in the Wings–Wasp Wings, That Is

Wing size differences between two Nasonia wasp species are the result of…

Entertainement

Coming soon

Your one-stop resource for medical news and education.

Your one-stop resource for medical news and education.
Sign Up for Free

You Might Also Like

Game-Changer in Emergency Medicine: New AI Test Flags Sepsis Hours Before Symptoms Worsen

By Admin

Perfumes and lotions disrupt how body protects itself from indoor air pollutants

By Admin
Health

Medical Milestone: Surgeons Perform First-Ever Human Bladder Transplant

By Admin

A Downside of Taurine: It Drives Leukemia Growth

By Admin
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Editorial Policy
  • Accessibility Statement
  • Contact US
  • Feedback
  • Advertisement
More Info
  • Newsletter
  • Beauty Lab
  • News & Perspective
  • Food & Diet
  • Health
  • Environment
  • Anatomy

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

Copyright © 2023 ScienceAbode. All Rights Reserved. Designed and Developed by Spirelab Solutions (Pvt) Ltd

Welcome Back!

Sign in to your account

Lost your password?